Drug Discovery & Development | Cell Therapeutics Reveals Drug Portfolio Progress, Outlook For 2014 - Update NASDAQ ... change the primary endpoint of the Phase 3 PIX-R, or PIX306, post-marketing commitment study of pixantrone-rituximab versus gemcitabine-rituximab for patients with relapsed B-cell non-Hodgkin lymphoma from overall survival to progression-free survival. Cell Therapeutics reaquire rights to two anti-cancer compounds from Novartis Cell Therapeutics Inc.: Cell Therapeutics Announces 2014 Outlook and Recent ... |
